Table 5.
Relationship of cervical screening results and ovarian cancer diagnoses of any histology or grade and the time interval statistics between the two.
| Cytology | HPV | N (Tests) | N (Cancers) | % of Cancers | Risk | 95%CI |
|---|---|---|---|---|---|---|
| Missing | Any¥ | 15,769 | 2 | 0.18% | 0.01% | 0.00–0.05% |
| NILM | Any | 2,180,297 | 1,055 | 94.79% | 0.05% | 0.05–0.05% |
| Other † | Any | 150 | 2 | 0.18% | 1.33% | 0.16–4.73% |
| ASC-US | Any | 109,551 | 20 | 1.80% | 0.02% | 0.01–0.03% |
| LSIL | Any | 53,813 | 10 | 0.90% | 0.02% | 0.01–0.03% |
| ASC-H | Any | 9,783 | 1 | 0.09% | 0.01% | 0.00–0.06% |
| AGC | Any | 8,638 | 17 | 1.53% | 0.20% | 0.11–0.31% |
| HSIL/AIS | Any | 7,570 | 4 | 0.36% | 0.05% | 0.01–0.14% |
| SCC | Any | 158 | 2 | 0.18% | 1.27% | 0.15–4.50% |
| HG cytology‡ | Any | 26,149 | 24 | 2.16% | 0.09% | 0.06–0.14% |
| HG cytology‡ or Other† | Any | 26,299 | 26 | 2.34% | 0.10% | 0.06–0.14% |
| ASC-US+§ | Any | 189,513 | 54 | 4.85% | 0.03% | 0.02–0.04% |
| ASC-US+§ or Other† | Any | 189,663 | 56 | 5.03% | 0.03% | 0.02–0.04% |
| AGC | Negative | 5,782 | 16 | 1.44% | 0.28% | 0.16–0.45% |
| HG cytology‡ | Negative | 8,398 | 17 | 1.53% | 0.20% | 0.12–0.32% |
| HG cytology‡ or Other† | Negative | 8,501 | 19 | 1.71% | 0.22% | 0.13–0.35% |
| ASC-US+§ | Negative | 60,951 | 30 | 2.70% | 0.05% | 0.03–0.07% |
| ASC-US+§ or Other† | Negative | 61,054 | 32 | 2.88% | 0.05% | 0.04–0.07% |
| NILM | Positive | 105,879 | 16 | 1.44% | 0.02% | 0.01–0.02% |
| Any | Missing | 270,915 | 54 | 4.85% | 0.02% | 0.01–0.03% |
| Any | Negative | 1,892,808 | 1,021 | 91.73% | 0.05% | 0.05–0.06% |
| Any | Positive | 222,006 | 38 | 3.41% | 0.02% | 0.01–0.02% |
| Any | Any | 2,385,729 | 1,113 | 100.00% | 0.05% | 0.04–0.05% |
Abbreviations: SCC, squamous cell carcinoma; HSIL, high-grade squamous intraepithelial lesion; AIS, adenocarcinoma in situ; AGC, atypical glandular cells; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy; HG = high-grade cytology
One-sided, 97.5% confidence interval
Time between co-test and endometrial cancer diagnosis in days
Other=interpretations of non-cervical changes, primarily of uterine, extra-uterine, or endometrial adenocarcinoma or carcinoma not otherwise specified
ASC-H, AGC, HSIL/AIS, and SCC (excludes Other)
All non-normal cytology (excludes Other)
Excluding HPV missing